• DNDi - Best Science for the Most Neglected 20 Years
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Filaria: river blindness
      • Mycetoma
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Dengue
      • COVID-19
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies and IP
      • Children’s health
      • Gender equity
      • Climate change
      • AI and new technologies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • Dengue Alliance
      • HAT Platform
      • HELP Helminth Elimination Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi DRC
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
      • DNDi Southern Africa
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
DNDi - Best Science for the Most Neglected 20 Years
  • DNDi - Best Science for the Most Neglected 20 Years
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Filaria: river blindness
      • Mycetoma
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Dengue
      • COVID-19
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies and IP
      • Children’s health
      • Gender equity
      • Climate change
      • AI and new technologies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • Dengue Alliance
      • HAT Platform
      • HELP Helminth Elimination Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi DRC
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
      • DNDi Southern Africa
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
Home > Diseases
paediatric-hiv icon

Paediatric HIV

Symptoms, transmission, and current treatments for paediatric HIV

Home > Diseases
paediatric-hiv icon

Paediatric HIV

Symptoms, transmission, and current treatments for paediatric HIV

  • Overview
  • Facts
  • Projects & achievements
  • Target product profile
  • Advocacy toolkit

What is HIV?

The human immunodeficiency virus (HIV) is a virus that weakens the immune system, making the body less able to fight infections and cancers. Without treatment, HIV continues replicating within the body leading to an advanced stage of HIV infection called Acquired Immunodeficiency Syndrome (AIDS). At this stage, the body is very vulnerable to infections and cancers that can typically be fought by a healthy immune system, leading to chronic illness and death.

However, antiretroviral drugs are generally expensive, and there is not enough access to diagnostic tests and treatments in low- and middle-income countries.

Babies and young children with HIV are particularly vulnerable, with most not surviving to the age of five without treatment. Transmission of the HIV virus from a pregnant mother to a child can be easily prevented with current treatments, but a high number of paediatric infections still occur in some developing countries despite global progress in the prevention of mother-to-child transmission.

What is the impact of paediatric HIV?

  • 1.7 million children living with HIV
  • 160,000 new HIV cases in children in 2021
  • 82% of children diagnosed with HIV in 2021 live in sub-Saharan Africa
  • Only 52% of children with HIV receive treatment – compared to 76% of adults with HIV
  • Without treatment, half of children with HIV will die before turning two
  • Children comprised 4% of people living with HIV in 2021 but 15% of AIDS-related deaths

How is HIV in children treated?

At present, HIV cannot be cured, but it can be managed with combinations of antiretroviral drugs. However, due to the relatively low number of children living with HIV compared to adults, research on new HIV medicines specifically for children has been neglected.

The World Health Organization (WHO) recommends first-line treatment for babies and children of a boosted protease inhibitor with two nucleoside reverse transcriptase inhibitors in a combination of ABC + 3TC or ZDV + 3TC. Until recently, the only protease inhibitor available for young children was LPV/r, available in a form that was:

  • not child-friendly (the syrup tastes terrible and contains 42% alcohol)
  • not suitable for poor communities because it needs to be stored in a fridge
  • difficult to store and transport.

Together with our partner Cipla, we have developed sweet-tasting, heat-stable, ‘4-in-1’ granules to treat young children, which were approved by the South African Health Products Regulatory Authority (SAHPRA) in 2022. Carers can give the medicine to children by sprinkling the granules over soft food like porridge or dissolving it in water or milk.

Multiple new child-friendly formulations of WHO-recommended regimens are now being introduced – including paediatric formulations of dolutegravir-containing regimens – representing a long-awaited and long overdue treatment revolution for children with HIV.

For children with both HIV and TB, WHO guidelines now recommend a ‘superbooster’ therapy we developed that has improved treatment results.

UNAIDS targets state that 95% of children should be on treatment by 2025. More child-friendly medicines are needed to roll-out treatment to more babies and young children, who are either receiving no treatment or suboptimal treatments. Access is also a problem: only 52% of children with HIV received antiretroviral treatment in 2021.

What new treatments for paediatric HIV are needed?

A better treatment for babies and young children would ideally be safe, easy to give, well-tolerated and palatable, heat-stable, and readily dispersible in commonly used food and liquids. It must also carry minimal risk for developing resistance, be compatible with drugs against tuberculosis, and affordable.

What paediatric HIV treatments are we working on?

We aim to help end the neglect of paediatric HIV by developing optimal child-friendly antiretroviral formulations for children living with HIV, with a special focus on babies and young children who are at the highest risk of dying without treatment.

Find out more about our work developing treatments for paediatric HIV

How do children get HIV?

  • 90% of babies with HIV acquired the virus from their HIV-positive mothers during pregnancy, delivery, or through breast-feeding.
  • Effective treatment can prevent HIV transmission from a mother to her child, but not all HIV-infected pregnant women have access to these treatments.

What is the effect of HIV on children?

Babies with HIV develop the same symptoms as adults, but the disease progresses faster. Symptoms include:

  • slow growth and weight gain
  • severe wasting
  • diarrhoea and upper respiratory tract infections that cause increased medical problems and death
  • infections such as tuberculosis

How is HIV in children diagnosed?

Rapid HIV-antibody tests have made field diagnosis of HIV inexpensive and technically feasible in poor communities.

Last updated: December 2022

Read about how Uganda is rolling out better ‘point-of-care’ early infant diagnostics

READ MORE

Making medical history for neglected patients

We develop urgently needed treatments for neglected patients and ensure they’re affordable, available, and adapted to the communities who need them

Young boy sitting on a hospital bed being examined by a nurse

Chagas disease

Causes heart and vital organ damage, after people are bitten by blood-sucking bugs

We delivered the first-ever treatment for children; now we’re searching for new drug candidates and working to boost access to care

Healthcare workers in a hospital

COVID-19

Devasting and deadly to many, there’s too little research to help the most vulnerable

We’re accelerating research by coordinating clinical trials in low-resource settings and bringing together partners

Patient medical examination

Cryptococcal meningitis

Without treatment, deadly for thousands of people with advanced HIV

We’re working to improve access to life-saving treatments and developing an easier-to-use formulation

Girl with skin lesions on her nose

Cutaneous leishmaniasis

Leaves disfiguring, life-long scars that lead to severe social stigma

We’re working to develop safer, shorter treatments for this disabling disease

Dengue

Rapidly spreading climate-sensitive disease with no specific treatment

We’re building a global partnership with dengue-endemic countries to develop a first treatment

Father walking in rural village with a cane and holding his son's hand

Filaria: river blindness

Lead to unbearable itching, disfiguring skin lesions, and even blindness

We’re working to develop a safe, effective, and affordable drug for the prevention and treatment of this debilitating disease

Young man standing in the street

Hepatitis C

Millions are left without treatment even though effective drugs exist

We’ve delivered a treatment as simple, safe, and effective as the best drugs available today – at a fraction of the cost 

Woman standing in front of her door house in a rural village in Sudan

Mycetoma

Often ends in amputation​, after people get infected from stepping on a thorn

We’re conducting the world’s first trial for an alternative to current treatments, which are toxic and ineffective

Mother holding her baby in her arms smiling

Paediatric HIV

Without treatment, half of children die before their second birthday

We’ve developed a strawberry-flavoured treatment to meet the needs of children long neglected by the global HIV response

Doctor diagnosing a man in a village with his hands on the man's neck

Sleeping sickness

Transmitted by the bite of a tsetse fly and causes severe neurological disorders

We delivered a revolutionary new drug to replace toxic treatments, and have ongoing trials to eliminate this disease

Girl looking over a fence

Visceral leishmaniasis

Is one of the world’s biggest parasitic killers, spread by the bites of sandflies

We’re working to develop a new generation of treatments to replace drugs that are painful, ineffective, and cause side effects

Chagas disease

COVID-19

Cryptococcal meningitis

Cutaneous leishmaniasis

Dengue

Filaria: river blindness

Hepatitis C

Mycetoma

Paediatric HIV

Sleeping sickness

Visceral leishmaniasis

VIEW ALL DISEASES

Stay connected

Get our latest news, personal stories, research articles, and job opportunities. 

DNDi - Best Science for the Most Neglected 20 Years
Facebook-f
Twitter
Instagram
Linkedin-in
Youtube
International non-profit developing safe, effective, and affordable treatments for the most neglected patients.

Learn more

  • Diseases
  • Neglected tropical diseases
  • R&D portfolio
  • Policy advocacy

Get in touch

  • Our offices
  • Contact us
  • Integrity Line

Support us

  • Donate
  • Subscribe to eNews

Work with us

  • Join research networks
  • Jobs
  • RFPs
  • Terms of Use   
  •   Acceptable Use Policy   
  •   Privacy Policy   
  •   Cookie Policy   
  •   Our policies   

  • Except for images, films and trademarks which are subject to DNDi’s Terms of Use, content on this site is licensed under a Creative Commons Attribution-NonCommercial-Share Alike 3.0 Switzerland License   
We use cookies to track our audience and improve our content. By clicking 'Accept All', you are agreeing to our use of cookies. Click on 'Customize' to accept only some cookies.
Customize
REJECT ACCEPT ALL
Manage consent

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
CookieDurationDescription
cookielawinfo-checkbox-advertisement1 yearSet by the GDPR Cookie Consent plugin, this cookie is used to record the user consent for the cookies in the "Advertisement" category .
cookielawinfo-checkbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
CookieLawInfoConsent1 yearRecords the default button state of the corresponding category & the status of CCPA. It works only in coordination with the primary cookie.
PHPSESSIDsessionThis cookie is native to PHP applications. The cookie is used to store and identify a users' unique session ID for the purpose of managing user session on the website. The cookie is a session cookies and is deleted when all the browser windows are closed.
viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
Functional
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
CookieDurationDescription
elementorneverThis cookie is used by the website's WordPress theme. It allows the website owner to implement or change the website's content in real-time.
Analytics
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
CookieDurationDescription
_ga2 yearsThe _ga cookie, installed by Google Analytics, calculates visitor, session and campaign data and also keeps track of site usage for the site's analytics report. The cookie stores information anonymously and assigns a randomly generated number to recognize unique visitors.
_ga_16Q5RH3XRG2 yearsThis cookie is installed by Google Analytics.
_gat_UA-10302561-11 minuteA variation of the _gat cookie set by Google Analytics and Google Tag Manager to allow website owners to track visitor behaviour and measure site performance. The pattern element in the name contains the unique identity number of the account or website it relates to.
_gid1 dayInstalled by Google Analytics, _gid cookie stores information on how visitors use a website, while also creating an analytics report of the website's performance. Some of the data that are collected include the number of visitors, their source, and the pages they visit anonymously.
_hjAbsoluteSessionInProgress30 minutesHotjar sets this cookie to detect the first pageview session of a user. This is a True/False flag set by the cookie.
_hjFirstSeen30 minutesHotjar sets this cookie to identify a new user’s first session. It stores a true/false value, indicating whether it was the first time Hotjar saw this user.
_hjIncludedInPageviewSample2 minutesHotjar sets this cookie to know whether a user is included in the data sampling defined by the site's pageview limit.
_hjIncludedInSessionSample2 minutesHotjar sets this cookie to know whether a user is included in the data sampling defined by the site's daily session limit.
_hjSession_112884430 minutesHotjar sets this cookie.
_hjSessionUser_11288441 yearHotjar sets this cookie.
CONSENT2 yearsYouTube sets this cookie via embedded youtube-videos and registers anonymous statistical data.
Targeting
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
SAVE & ACCEPT
Powered by CookieYes Logo